The conserved 324^{324}GDIR327^{327} peptide region at the base of the V3 loop of the HIV-1 envelope glycoprotein gp120, together with its camouflaging N301 and N332 glycans, is a major target of broadly neutralizing antibodies (bnAbs) and overlaps the CCR5 coreceptor-binding surface. Sok et al. (2016) showed that bnAbs of the GDIR-glycan class all contact residues D325, R327 and H330, depend on the N301/N332 glycans, and are less effective against CXCR4-tropic (X4) viruses, while CD4-induced (CD4i) antibodies contacting the same residues are narrow. The unresolved problem is to explain and map, mechanistically and longitudinally, how functional constraint and glycan camouflage jointly govern antibody recognition and immune-driven evolution at this site: why CD4i antibodies contacting the same V3-base residues lack the breadth and potency of GDIR-glycan bnAbs; how antibody pressure drives N301/N332 glycan and GDIRQAH peptide evolution (including during CCR5-to-CXCR4 coreceptor switching); whether the CD4-competition/allostery measured on cell-surface trimers holds for monomeric gp120; and to what extent resistance of X4-tropic viruses limits the prophylactic and therapeutic utility of GDIR-glycan bnAbs.

Background

HIV-1 entry into host cells is mediated by the envelope glycoprotein (Env), a trimer of gp120/gp41 heterodimers on the viral surface. Gp120 binds the cellular receptor CD4 and then a coreceptor, most often the chemokine receptor CCR5 (R5-tropic virus) or, in later infection, CXCR4 (X4-tropic); coreceptor switching from CCR5 to CXCR4 accompanies faster CD4 T-cell decline in roughly half of untreated infections. Because Env is the sole target of neutralizing antibodies, it is heavily decorated with N-linked glycans forming a "glycan shield" that camouflages peptide epitopes. A few infected individuals nevertheless develop broadly neutralizing antibodies (bnAbs) against conserved Env regions; one major region is the "high-mannose patch" (also called the N332 supersite or V3-glycan site), a cluster of oligomannose-type glycans centered on the N332 glycan at the base of the V3 loop. The V3 loop itself mediates coreceptor binding: its conserved base, including the 324^{324}GDIRQAH330^{330} peptide region (HXB2 numbering, with the core motif 324^{324}GDIR327^{327}), contributes to the CCR5-binding surface. Sok et al. (Immunity 2016) isolated new bnAb families (PGDM11–14, PGDM21) targeting this region and showed that all GDIR-glycan bnAbs, including the previously known PGT121/PGT128/PGT135 classes, contact residues D325, R327 and H330 and depend to varying degrees on the N332 and N301 glycans; that mutations at D325 and R327 impair CCR5 N-terminal peptide binding, tying antibody recognition to coreceptor function; that among 42,715 cross-clade Env sequences, mutations at D325/R327/H330 are more frequent precisely when the N301 or N332 glycan sites are absent, indicating selection at this peptide region when its glycans are lost; and that GDIR-glycan bnAbs neutralize X4-tropic viruses, which vary more in this region, less well than R5-tropic viruses. CD4-induced (CD4i) antibodies are a class of antibodies (e.g., 17b, X5, 412d) whose epitopes — the V3 base plus the gp120 "bridging sheet", a four-stranded beta sheet formed only after CD4-induced rearrangement of Env into an open conformation — are exposed mainly after CD4 engages. Env strains are also classified by neutralization tier: tier-1 viruses are readily neutralized and sample open conformations, while tier-2 (primary-isolate) viruses are neutralization-resistant and prefer the closed, prefusion trimer conformation that occludes CD4i epitopes. Sok et al. found that GDIR-glycan bnAbs, unlike CD4i antibodies, bind native closed trimers without CD4 and can allosterically inhibit soluble-CD4 binding, and speculated that only antibodies with long CDR H3 loops (hypervariable third heavy-chain loops) that penetrate the camouflaging glycans can neutralize broadly. They explicitly left open: (1) the longitudinal dynamics of antibody pressure versus Env glycan/peptide evolution at this site — they lacked longitudinal donor samples and could only cite an older coreceptor-switching study (van Rij et al. 2000) in which N301 loss and/or 324^{324}GDIRQAH330^{330} mutations followed R5-to-X4 switching; (2) the mechanistic reason CD4i antibodies contacting the same residues lack the breadth and potency of GDIR-glycan bnAbs; (3) whether their cell-surface-trimer allostery/CD4-competition measurements would hold on monomeric gp120; (4) a comprehensive map of how glycan-site presence/absence (notably N301 versus N332/N334 competition) and local glycoform heterogeneity are modulated under immune pressure in natural infection; and (5) how far X4-virus resistance limits bnAb prophylactic and therapeutic utility.

Problem Statement

The problem, as raised by Sok et al. (Immunity 2016) and left open after subsequent progress, is to understand how functional constraint and glycan camouflage jointly govern antibody recognition and immune-driven evolution of the HIV-1 envelope V3-base 324^{324}GDIR327^{327}/324^{324}GDIRQAH330^{330} site, through four linked questions: (1) Mechanistic recognition: provide a direct structural and functional delineation of why CD4-induced antibodies that contact the same V3-base residues (e.g., 17b, X5, 412d) lack the neutralization breadth and potency of GDIR-glycan bnAbs — testing, rather than merely speculating, the proposed distinction between CD4i antibodies requiring the open trimer/bridging-sheet conformation and GDIR-glycan bnAbs penetrating the glycan shield of native closed trimers with long CDR H3 loops; (2) Longitudinal evolution: map, with donor-matched longitudinal sampling of viruses and antibodies, whether and how antibody pressure drives loss of the N301 (and N332) glycans and mutations in the GDIRQAH region during natural infection, including during CCR5-to-CXCR4 coreceptor switching, and comprehensively characterize how glycan-site presence/absence and local glycoform heterogeneity at this site are modulated under immune pressure across sequences and phenotypes; (3) Binding-mode reconciliation: determine whether the allosteric inhibition of CD4 binding and lack of competition with CD4i antibodies observed for GDIR-glycan bnAbs on cell-surface Env trimers also hold on monomeric gp120, reconciling trimeric versus monomeric binding modes; (4) Clinical consequence: quantify the extent to which the relative resistance of CXCR4-tropic viruses to GDIR-glycan bnAbs limits the prophylactic and therapeutic utility of these antibodies in diverse patient populations and disease stages. These components share one scientific objective — a causal, mechanistic account of the balance between CCR5-binding function and antibody escape at this camouflaged conserved motif — and an answer is complete when each component is settled by direct evidence (or shown not to obtain) for the site as defined in the source work, without restricting to particular isolates, clades, or antibody families beyond what the evidence requires.

References

  1. Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, Hsueh J, Ramos A, Le KM, Jones M, Jardine JG, Bastidas R, Sarkar A, Liang C-H, Shivatare SS, Wu C-Y, Schief WR, Wong C-H, Wilson IA, Ward AB, Zhu J, Poignard P, Burton DR. A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity 45(1):31-45 (2016). DOI: 10.1016/j.immuni.2016.06.026. https://doi.org/10.1016/j.immuni.2016.06.026 (full text: PMCID PMC4990068)
  2. van Rij RP, Blaak H, Visser JA, Brouwer M, Rientsma R, Broersen S, de Roda Husman AM, Schuitemaker H. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. Journal of Clinical Investigation 106(8):1039-1052 (2000). DOI: 10.1172/JCI7953. https://doi.org/10.1172/JCI7953
  3. Boliar S, Patil S, Shukla BN, Ghobbeh A, Deshpande S, Chen W, Guenaga J, Dimitrov DS, Wyatt RT, Chakrabarti BK. Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category. Virology 519:99-105 (2018). DOI: 10.1016/j.virol.2018.04.002. https://doi.org/10.1016/j.virol.2018.04.002
  4. Tolbert WD, Sherburn R, Gohain N, Ding S, Flinko R, Orlandi C, Ray K, Finzi A, Lewis GK, Pazgier M. Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site. BMC Biology 18:91 (2020). DOI: 10.1186/s12915-020-00819-y. https://doi.org/10.1186/s12915-020-00819-y
  5. Registre L, Moreau Y, Ataca ST, Pulukuri S, Henrich TJ, Lin N, Sagar M. HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility. Journal of Virology 94(2):e01604-19 (2020). DOI: 10.1128/JVI.01604-19. https://doi.org/10.1128/JVI.01604-19
  6. Granger LA, Huettner I, Debeljak F, Kaleebu P, Schechter M, Tambussi G, Weber J, Miro JM, Phillips R, Babiker A, Cooper DA, Fisher M, Ramjee G, Fidler S, Frater J, Fox J, Doores KJ. Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort. AIDS 35(13):2073-2084 (2021). DOI: 10.1097/QAD.0000000000002988. https://doi.org/10.1097/QAD.0000000000002988
  7. Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, Monczor AN, Lupo S, Gelderblom HC, Ansel JL, Kanjilal DG, Maxfield LF, Nkolola J, Borducchi EN, Abbink P, Liu J, Peter L, Chandrashekar A, Nityanandam R, Lin Z, Setaro A, Sapiente J, Chen Z, Sunner L, Cassidy T, Bennett C, Sato A, Mayer B, Perelson AS, deCamp A, Priddy FH, Wagh K, Giorgi EE, Yates NL, Arduino RC, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine 27(10):1718-1724 (2021). DOI: 10.1038/s41591-021-01509-0. https://doi.org/10.1038/s41591-021-01509-0
  8. Marichannegowda MH, Song H. Immune escape mutations selected by neutralizing antibodies in natural HIV-1 infection can alter coreceptor usage repertoire of the transmitted/founder virus. Virology 568:72-76 (2022). DOI: 10.1016/j.virol.2022.01.010. https://doi.org/10.1016/j.virol.2022.01.010
  9. Zacharopoulou P, Ansari MA, Frater J. A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117. Current Opinion in HIV and AIDS 17(6):352-358 (2022). DOI: 10.1097/COH.0000000000000764. https://doi.org/10.1097/COH.0000000000000764
  10. Marichannegowda MH, Zemil M, Wieczorek L, Sanders-Buell E, Bose M, O'Sullivan AM, King D, Francisco L, Diaz-Mendez F, Setua S, Chomont N, Phanuphak N, Ananworanich J, Hsu D, Vasan S, Michael NL, Eller LA, Tovanabutra S, Tagaya Y, Robb ML, Polonis VR, Song H. Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study. EBioMedicine 98:104867 (2023). DOI: 10.1016/j.ebiom.2023.104867. https://doi.org/10.1016/j.ebiom.2023.104867
  11. Marichannegowda MH, Setua S, Bose M, Sanders-Buell E, King D, Zemil M, Wieczorek L, Diaz-Mendez F, Chomont N, Thomas R, Francisco L, Eller LA, Polonis VR, Tovanabutra S, Heredia A, Tagaya Y, Michael NL, Robb ML, Song H. Transmission of highly virulent CXCR4 tropic HIV-1 through the mucosal route in an individual with a wild-type CCR5 genotype. EBioMedicine 109:105410 (2024). DOI: 10.1016/j.ebiom.2024.105410. https://doi.org/10.1016/j.ebiom.2024.105410
  12. Radford CE, Bloom JD. Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains. Journal of Virology 99(5):e0019525 (2025). DOI: 10.1128/jvi.00195-25. https://doi.org/10.1128/jvi.00195-25
  13. Foulkes C, Friedrich N, Ivan B, Stiegeler E, Magnus C, Schmidt D, Karakus U, Weber J, Günthard HF, Pasin C, Rusert P, Trkola A. Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity. PLoS Pathogens 21(1):e1012825 (2025). DOI: 10.1371/journal.ppat.1012825. https://doi.org/10.1371/journal.ppat.1012825
  14. Gieselmann L, DeLaitsch AT, Rohde M, Radford C, Worczinski J, Ashurov A, Ahmadov E, Burger JA, Havenar-Daughton C, Deshpande S, Giovannoni F, Corti D, Kreer C, Ercanoglu MS, Schommers P, Georgiev IS, West AP Jr, Knüfer J, Stumpf R, Kroidl A, Geldmacher C, Maganga L, William W, Ntinginya NE, Hoelscher M, Yang Z, Wei Q, Renfrow MB, Green TJ, Novak J, van Gils MJ, Gristick HB, Gruell H, Bloom JD, Seaman MS, Bjorkman PJ, Klein F. Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332(gp120) glycan-independent epitope. Nature Immunology 27(3):572-585 (2026). DOI: 10.1038/s41590-025-02385-3. https://doi.org/10.1038/s41590-025-02385-3
  15. Tao K, Herschhorn A, Fera D, Lynch RM, Julg BD, Korber B, Shafer RW. Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies. Communications Medicine 6(1):313 (2026). DOI: 10.1038/s43856-026-01680-w. https://doi.org/10.1038/s43856-026-01680-w